The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Novel approaches in multiple myeloma: what is unique about CELMoDs?

Jun 25, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farber Cancer Institute, Boston, US. In this podcast he discusses cereblon E3 ligase modulators (CELMoDs) as a novel approach in the treatment of relapsed/refractory multiple myeloma.

Paul Richardson describes how preclinical data have shown CC-92480 to have potent and direct anti-myeloma and immunostimulatory effects. He discusses the results from the phase I, multicenter, international study that combined CC-92480 with dexamethasone in patients with relapsed and refractory multiple myeloma and describes the two dosing regimens (continuous and intensive), patient characteristics, and safety data. Dr Richardson also explains that the results show encouraging, durable responses, particularly for patients that have triple-refractory myeloma, which are a sub-group of patients where there is a significant clinical unmet need.

Novel approaches in multiple myeloma: what is unique about CELMoDs?